Denosumab Demonstrates More Efficacy Than Zometa in Prostate Cancer Patients with Bone Metastases

A phase III study released at the ASCO meeting demonstrated that for men with bone metastases from prostate cancer, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. […]

The Survival Implications of Bone Mineral Loss

In a Town Hall discussion,  “Ablating Testosterone in Prostate Cancer and the Concomitant Negative Effects”,  Fred Saad, MD,  FRCS, Director of Urologic Oncology, Professor of Surgery/Urology, U of M Chair in Prostate Cancer; University of Montreal discussed the negative effects that bone loss resulting from hormone therapy (ADT)  poses to our life expectancy. His over [...]

Effects of Denosumab on Bone Mineral Density in Men Receiving ADT for Prostate Cancer

The relatively new drug, denosumab, has proven itself very effective for men on a hormone blockade (ADT). In a recently completed 3-year, randomized, double-blind study at the Massachusetts General Hospital Cancer Center, Boston, Massachusetts, denosumab significantly increased bone mineral density and decreased new vertebral fractures in men receiving ADT for the treatment of advanced prostate [...]

On the Horizon – Denosumab, An alternative To Zometa To Protect Bones While Treating Advanced Prostate Cancer

Second of Three Pivotal Phase Three Bone Metastases Trials Meets Primary Endpoint Denosumab Delayed Time to Skeletal Related Events Amgen (NASDAQ: AMGN) has announced positive results from a Phase III head-to-head trial evaluating denosumab administered subcutaneously, versus Zometa (zoledronic acid) administered as an intravenous (IV) infusion. Currently Zometa is the FDA approved treatment for bone [...]

Denosumab Increased Bone Mineral Density in Men With Nonmetastatic Prostate Cancer

Presented at EAU on March 23, 2009 The drug Denosumab has shown itself both easy to tolerate by patients as well highly able to increases bone mineral density (BMD) when compared with placebo in men with nonmetastatic prostate cancer receiving androgen deprivation therapy (ADT). The results of this multi-centre, randomized, double-blind, placebo-controlled, phase 3 study [...]

Denosumab for Bone Mineral Density (BMD)

Amgen just completed, with positive results, a three-year Phase 3 placebo-controlled trial which evaluated denosumab for the treatment of bone loss (reduction of bone mineral density –BMD) in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer. One of the more common and significant side effects of ADT is loss of BMD. This loss [...]

Go to Top